Pfizer-BioNTech phase 3 interim results – 90% effective

On November 9, 2020 Pfizer and BioNTech, together with Acuitas Therapeutics (the lipid nano-particle component) all announce their COVID-19 vaccine candidate had “achieved success”.  They claimed the “first interim analysis of Phase 3 study” showed “more than 90% effective in preventing COVID-19”.  Science by press release!

Pfizer’s CEO Dr. Albert Bourla stated: “I believe this is likely the most significant medical advance in the last 100 years, if you count the impact this will have in public health, global economy.”

“Dr. Scott Gottlieb, a former FDA commissioner and a member of Pfizer’s board, told CNBC the vaccine could be available in limited use as early as late December and widely available by the third quarter of 2021.”

The press went wild promoting the “stunning” 90% efficacy: [1, 2, 3, 4, 5]